Extended Access to Momelotinib for Adults with Myelofibrosis

Sponsor: GlaxoSmithKline

Sponsor score: 60

ClinicalTrials ID:NCT03441113

Provider View

This study offers continued access to the medication momelotinib for patients with myelofibrosis who are already participating in certain clinical trials. It aims to monitor the long-term safety of the drug and assess survival outcomes.

Patient Parameters

Program Overview

The main goal of this study is to allow patients with myelofibrosis, who are already part of specific clinical trials, to continue using the medication momelotinib. The study will also check the long-term safety of the drug and track how well patients are doing in terms of survival and avoiding leukemia. Participants will continue taking momelotinib in tablet form, with doses available in 50mg, 100mg, 150mg, and 200mg, as long as their disease has not worsened.

Eligibility Criteria

Inclusion Criteria

  • Currently participating in one of the following studies: GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301.
  • Able to understand and willing to sign the consent form.

Exclusion Criteria

  • Known allergy to momelotinib or any of its ingredients.

Note: There may be other specific criteria for inclusion or exclusion.

Locations

FACILITYZIPCITYSTATE
IC Irvine Health92868OrangeCalifornia
GSK Investigational Site94305-5821StanfordCalifornia
Stanford Hospital and Clinics94305StanfordCalifornia
GSK Investigational Site80045AuroraColorado
University of Colorado Cancer Center80045AuroraColorado
GSK Investigational Site32224JacksonvilleFlorida
Mayo Clinic Florida32224JacksonvilleFlorida
GSK Investigational Site33612TampaFlorida
Moffitt Cancer Center33612TampaFlorida
GSK Investigational Site30322AtlantaGeorgia

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.